All Access Articles |
- Monopar Therapeutics Ends Q2 2026 with $134.3M Cash | 2026-08-12 | PHARMACEUTICAL
- FDA Grants Rare Pediatric Disease Designation to Monopar Therapeutics' ALXN1840 | 2026-06-30 | PHARMACEUTICAL
- Monopar Therapeutics Appoints Susan Rodriguez as Chief Commercial Officer | 2026-03-02 | UNITED STATES
- Monopar Therapeutics Reports Strong Q3 2025 Progress | 2025-11-13 | PHARMACEUTICAL